The Influence of Seamless Pharmaceutical Care for patients in Chronic Obstructive Pulmonary Disease Clinic at Phaholpolpayahasena Hospital, Kanchanaburi Province
Article Sidebar
Main Article Content
Abstract
Objective: To evaluate influence of seamless pharmaceutical care by comparing outcomes of the treatment of patients with chronic obstructive pulmonary disease (COPD) and quality of life between study groups receiving pharmaceutical care and control group receiving usual care Methods: This research was a pilot study. The researchers randomly allocated 60 patients into study or control group, each with 30 patients. Patients in the study group received pharmaceutical care 4 times during their hospital visits, starting at their hospitalization as in-patients and later at the COPD clinic when patients, after hospital discharge, returned for further treatment as ambulatory patients. Control group received usual care. Both groups of patients were assessed for various outcomes at 3 months after being discharged. Results: At the end of study, patients in the study group, compared to those in control, had a significantly lower rate of emergency room visits and hospital admissions (P=0.002, P=0.006), a significantly lower score on dyspnea (mMRC score)(P=0.022), and a significantly higher level of peak expiratory flow rate (PEFR) (P=0.025) and quality of life (CAT score) than (P<0.001). Conclusion: Seamless pharmaceutical care helps decrease the number of emergency visits, hospitalization and dyspnea. It also improves lung function leading to a better quality of life.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Word Heath Organization. Chronic obstructive pul monary disease [online]. 2012 [cited Dec12, 2016]. Available from: www.who.int/respiratory/copd/an/.
3. Global Initiative for Chronic Obstructive Lung Disease. Global initiative for chronic obstructive lung disease pocket guide to COPD diagnosis manage ment and prevention a guide for health care professionals. 2017. 2017 [cited Jan15, 2018]. Available from: www.goldcopd.org/wp-content/upload s/2016/12/wms-GOLD-2017-Pocket-Guide.pdf.
4. Lim S, Lam DC, Muttalif AR, Yunus F, Wongtim S, Shetty V, et al. Impact of chronic obstructive pulmo- nary disease (COPD) in the Asia- Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med 2015; 14: 2-11
5. Bureau of Epidemiology, Department of Disease Control Ministry of Public Health. Chronic non-commu nicable disease surveillance report 2012. Weekly Epidemiology Surveillance Report Thailand. 2013; 44: 802-15.
6. Strategic and Planning Group, Bureau of Non Com municable Disease. Annual report 2015. Bangkok: WVO Officer of Printing Mill; 2016.
7. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemi ology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-94.
8. Phanphao W, Jenghua S, Supamoon W, Nakham A. Intervention on managing drug related problem in hospitalized patients with asthma and chronic obstru ctive pulmonary disease (COPD) in Buddachinaraj Phisanulok hospital. Naresuan University Journal 2005; 13: 51-9.
9. Luedphanithit N. Outcomes of pharmaceutical care in patients with chronic asthma at Dokkhamtai hospital. J Health Sci 2014; 23: 37-43.
10. Sangpum P, Sthapornnanon N, Poolsup N. Clinical outcomes and health related quality of life of pharma ceutical care prior to physician visit in asthma clinic. Thai Pharmaceutical and Health Science Journal 2010; 5: 23-30.
11. Trakarnkitwichit U. Effects of inpatient drug coun seling on compliance of asthmatic or COPD patients at Samutprakarn hospital [dissertation]. Nakornpa thom: Silpakorn University; 2002.
12. Kuwalairat P, Mayases P, Thongdang A. Assess ment of pharmaceutical care outcome on the patients with chronic obstructive pulmonary disease attending community hospital in Thailand. Isan Journal of Phar maceutical Sciences 2014; 10: 80-92.
13. Kingkaewjaroenchai S. Outcome of chronic obstruct tive pulmonary disease clinic at King Narai hospital Lopburi. Region 5 Medical Journal 2014; 5: 45-55.
14. Piyasiriwat C. Role of decentralized pharmacist at Phichit hospital [dissertation]. Bangkok: Chulalong korn University; 1996.
15. Chanatepaporn P. Assessment of pharmaceutical care in female-medical ward in university hospital. Srinagarind Medical Journal 2006; 21: 282-88.
16. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res 2016; 25: 1057-73.
17. Dejsomritrutai W, Nana A, Maranetra KN, Wong surakiat P, Chierakul N, Charoenratanakul S. Refe rence spirometric values for healthy lifetime non smokers in Thailand. J Med Assoc Thai 2000; 83: 457-66.
18. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first validation of the COPD assessment test. Eur Respir J 2009; 34: 648-54.
19. Jarab AS, Alqudah SG, Khdour M, Shamssain M, Mukattash TL. Impact of pharmaceutical care on health outcomes in patients with COPD. Int J Clin Pharm 2012; 34: 53-62.
20. Tommelein E, Mehuys E, Van Hees T, Adriaens E, Van Bortel L, Christiaens T, et al. Effectiveness of pharmaceutical care for patients with chronic obstruct tive pulmonary disease (PHARMACOP): a random- ized controlled trial. Br J Clin Pharmacol 2013; 77: 756-66.
21. Wei L, Yang X, Li J, Liu L, Luo H, Zheng Z, et al. Effect of pharmaceutical care on medication adhe rence and hospital admission in patients with chronic obstructive pulmonary disease: a randomized con- trolled study. J Thorac Dis 2014; 6: 656-62.
22. Friedo WD, Agnes CS, Peter JS, Joop HD. Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction. Thorax. 1992; 47: 162-66.
23. Srimaya P, Phiman W, Rattannachotpanich T. Impact of pharmaceutical care in ambulatory patients with chronic obstructive pulmonary disease. Thai Journal of Pharmacy Practice 2011; 3: 23-32.
24. Engstrom CP., Person LO., Larson S, Ryden A, Sullivan M. Function status and wellbeing in chronic obstructive pulmonary disease with regard to clinical parameter and smoking: A descriptive study. Thorax 1995; 51: 825-30.
25. Saroea HG. Chronic obstructive pulmonary disease: major objective of management. Postgrad Med 1993; 94: 113-22.
